ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

1-Year Outcomes of a Prospective, Open Label, Randomized, Controlled Trial of Standard vs Extended-Release Tacrolimus as Maintenance Monotherapy in Kidney Transplantation after Alemtuzumab Induction with Rapid Steroid Withdrawal (TAESR Trial)

A. McLean, K. Chan, J. Galliford, D. Goodall, R. Charif, M. Willicombe, C. Roufosse, T. Cook, D. Taube

Imperial College Kidney &
Transplant Centre, Hammersmith Hospital, London, United Kingdom
Imperial Clinical Trials Unit, Imperial College, London, United Kingdom
Department of Medicine, Imperial College, London, United Kingdom

Meeting: 2013 American Transplant Congress

Abstract number: B1098

Related Abstracts
  • Steroid Avoidance with Alemtuzumab Induction and Tacrolimus Monotherapy Gives Similar Outcomes to Basiliximab Induction with Tacrolimus / Mycophenolate Maintenance at Three Years
  • Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial

Background: Extended-release (ER, once daily) tacrolimus (Advagraf) has been shown to provide equivalent results to standard-release (SR, twice daily) tacrolimus in several regimens for maintenance immunosuppression after kidney transplantation, but not in the context of tacrolimus-based maintenance monotherapy.

Methods: We have undertaken a prospective, randomized controlled, investigator-led, single centre, open-label trial comparing ER with SR tacrolimus as maintenance monotherapy after alemtuzumab induction (1x30mg dose) and rapid steroid elimination at 7 days. 50 patients recieved SR twice daily tacrolimus (Prograf) and 52 ER once daily tacrolimus (Advagraf). Randomization was stratified for live vs deceased donors, and the groups were balanced with respect to, age, sex, ethnicity, primary renal diagnosis, and prior sensitisation.

Results: The primary outcome measure was survival with a functioning graft at 1 year, and did not differ significantly between the two groups (SR 96% vs ER 92% p=0.26). Rejection-free survival was SR 84%, ER 86% p=0.48.

There was no significant difference between the two arms in mean graft function(MDRD-eGFR at 1 year: SR 53.9 ml/min 95%CI 47.0-60.0, ER 54.0 95% CI 46.5-61.5), tacrolimus level (SR 7.73 ng/ml ER 7.39 ng/ml at 1 year) or dispersion of tacrolimus trough levels, or incidence of sub-clinical rejection or degree of interstitial fibrosis in surveillance biopsies taken at 3 months and 1 year post-transplant

Conclusions: Under alemtuzumab induction with rapid steroid elimination, once daily extended-release tacrolimus maintenance monotherapy provides equivalent one-year survival with functioning graft to standard-release twice daily tacrolimus, with a highly simplified once-daily, single-agent regimen.

McLean, A.: Grant/Research Support, Astellas Pharma.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

McLean A, Chan K, Galliford J, Goodall D, Charif R, Willicombe M, Roufosse C, Cook T, Taube D. 1-Year Outcomes of a Prospective, Open Label, Randomized, Controlled Trial of Standard vs Extended-Release Tacrolimus as Maintenance Monotherapy in Kidney Transplantation after Alemtuzumab Induction with Rapid Steroid Withdrawal (TAESR Trial) [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/1-year-outcomes-of-a-prospective-open-label-randomized-controlled-trial-of-standard-vs-extended-release-tacrolimus-as-maintenance-monotherapy-in-kidney-transplantation-after-alemtuzumab-induction-w/. Accessed January 23, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
    • Penis Transplantation: First U.S. Experience.
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Home
    • Search
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.